| Symbol
| FOXC2
| contributors: mct/npt - updated : 28-06-2014
|
| HGNC name
| forkhead box C2 (MFH-1, mesenchyme forkhead 1)
|
| HGNC id
| 3801
|
| corresponding disease(s)
|
LPDD
, YNS
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
| --over
|
| |
in metastatic cancer cells | | tumoral
|
|
| --over
|
|
in invasive ovarian cancer cell lines and tissues  | | constitutional
|
|
| --over
|
| |
in bone marrow mesenchymal stem cells (BMSCs), may promote osteogenic differentiation and inhibit adipogenic differentiation, and this effect can be mediated via activating the canonical Wnt-CTNNB1signaling pathway (PMId: 24122419) | | tumoral
|
|
| --over
|
| |
in esophageal squamous cell carcinoma with advanced tumor stage, lymph node metastasis, and lymphatic invasion | |
| Susceptibility
|
to varicose veins and hemorrhoids |
| Variant & Polymorphism
other
| mutations strongly associated with primary venous valve failure in both the superficial and deep veins in the lower limb (Mellor 2007) |
| 
|
Candidate gene
Marker
| Therapy target
| functional interference with FOXC2 or ANGPT2 might provide a therapeutic approach for prevention and treatment of obesity or its related disorders | |
| | |
|
| FOXC2 knockout mouse displaying anterior segment abnormalities,craniofacial,cardiovascular and vertebrate anomalies |